16 November 2026
What is behind GSK’s valuation gap to its rivals?Pharmaceutical giant GSK has traded at a persistent valuation discount to global peers due to investor anxieties around patent cliffs (loss of drug exclusivity) in its key HIV franchise and a perception that its research and development pipeline is not up to scratch.
CEO Luke Miels, who took over from Emma Walmsley at the beginning of 2026 has...